Forecasting Rare Disease Markets: Why Small Patient Populations Demand a More Rigorous Model
Rare disease markets have an odd commercial paradox built into them: the patient population is tiny, but the market opportunity can still be substantial. That's what makes forecasting them fundamental ...
Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet desp ...
Market Access Doesn’t Begin After Approval. It Begins with Evidence
Why the most successful commercial launches are built long before reimbursement discussions begin For years, market access has been treated as a milestone. From developing the therapy, to completing t ...